AB9674
Anti-Tau phospho Serine 199/202 Antibody
Chemicon®, from rabbit
Synonym(s):
Anti-Anti-DDPAC, Anti-Anti-FTDP-17, Anti-Anti-MAPTL, Anti-Anti-MSTD, Anti-Anti-MTBT1, Anti-Anti-MTBT2, Anti-Anti-PPND, Anti-Anti-PPP1R103, Anti-Anti-TAU, Anti-Anti-tau-40
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
phosphorylation (pSer199/pSer202)
Gene Information
human ... MAPT(4137)
General description
Tau is a neuronal microtubule-associated protein found predominantly on axons and functions to promote tubulin polymerization and stabilize microtubules. Tau, in its hyperphosphorylated form, is the major component of paired helical filaments (PHF), the building block of neurofibrillary lesions in Alzheimer′s disease (AD) brain. Hyperphosphorylated Tau is also found in neurofibrillary lesions in a range of other central nervous system disorders. Hyperphosphorylation impairs the microtubule binding function of Tau, resulting in the destabilization of microtubules in AD brains, ultimately leading to the degeneration of the affected neurons. Numerous serine/threonine kinases, including GSK-3beta, protein kinase A (PKA), cyclin-dependent kinase 5 (cdk5) and casein kinase II (CK2), phosphorylate Tau. Serines 199 and 202 are phosphorylated by GSK-3beta and have been linked to hereditary frontotemporal dementia. Serine 202 phosphorylation by cdk5, stimulated by the presence of microtubules, has been linked to hereditary neurodegenerative disease.
Specificity
Tau phosphoSerine 199/202. The antibody recognizes Tau pSerine 199/202 in samples of recombinant human Tau treated with GSK-3beta for 45 minutes. The reactivity of the antibody is blocked with the pSerine 199/202 peptide but not the non-phosphopeptide, tau phosphopeptide corresponding to pSerine 199, tau phosphopeptide corresponding to pSerine 202 or a generic phosphoSerine-containing peptide.
Immunogen
Synthetic peptide of amino acids surrounding the phosphoSerine 199 and 202 sites of human Tau.
Application
Detect Tau phospho Serine 199/202 using this Anti-Tau phospho Serine 199/202 Antibody validated for use in WB.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
Western blot: 1:1,000. Suggested blocking buffer is 5% BSA-TBST overnight at 2-8°C. Suggested antibody dilution buffer is 3% BSA-TBST. Suggested antibody incubation time is 2 hours at room temperature.
Optimal working dilutions must be determined by the end user.
Optimal working dilutions must be determined by the end user.
Storage and Stability
Maintain at -20°C in undiluted for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles. Do not store in a self defrosting freezer.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Siranjeevi Nagaraj et al.
International journal of molecular sciences, 22(7) (2021-05-01)
MicroRNAs have been demonstrated as key regulators of gene expression in the etiology of a range of diseases including Alzheimer's disease (AD). Recently, we identified miR-483-5p as the most upregulated miRNA amongst a panel of miRNAs in blood plasma specific
Norimichi Shirafuji et al.
International journal of molecular sciences, 19(3) (2018-03-23)
Increased plasma homocysteinemia is considered a risk factor of dementia, including Alzheimer's disease (AD) and vascular dementia. However, the reason elevated plasma homocysteinemia increases the risk of dementia remains unknown. A pathological hallmark of AD is neurofibrillary tangles (NFTs) that
Fangfang Qi et al.
Molecular psychiatry (2023-06-07)
Activation of innate immunity in the brain is a prominent feature of Alzheimer's disease (AD). The present study investigated the regulation of innate immunity by wild-type serum injection in a transgenic AD mouse model. We found that treatment with wild-type
Alexandra Marquez et al.
Neurobiology of disease, 151, 105273-105273 (2021-01-23)
Pathological hyperphosphorylated tau is a key feature of Alzheimer's disease (AD) and Frontotemporal dementia (FTD). Using transgenic mice overexpressing human non-mutated tau (htau mice), we assessed the contribution of tau to peripheral and central neurodegeneration. Indices of peripheral small and
Haitao Tu et al.
BMC neuroscience, 23(1), 3-3 (2022-01-06)
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are common age-related neurodegenerative diseases comprising Lewy body spectrum disorders associated with cortical and subcortical Lewy body pathology. Over 30% of PD patients develop PD dementia (PDD), which describes dementia arising
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service